R. Bhurayanontachai, Pisud Siripaitoon, Narongdet Kositpantawong, S. Chusri
{"title":"2019冠状病毒病(COVID-19)相关急性呼吸窘迫综合征(CARDS)非abo相同恢复期血浆输注成功一例","authors":"R. Bhurayanontachai, Pisud Siripaitoon, Narongdet Kositpantawong, S. Chusri","doi":"10.54205/ccc.v30.254752","DOIUrl":null,"url":null,"abstract":"Coronavirus disease 2019 (COVID-19) is pandemic with substantial fatality without specific treatment. Convalescent plasma is used to treat infectious diseases including severe acute respiratory syndrome coronavirus 1 and Middle East respiratory syndrome coronavirus infection, because of the effect of direct neutralizing and suppression of viremia, and immunomodulation effect. Although several anti-cytokine agents were suggested to improve outcomes of the patient, the unavailability of drugs will be a major problem for accessing. We reported the experience of convalescent plasma transfusion for COVID-19 related acute respiratory distress syndrome (CARDS), who refractory to standard treatment and clinically improvement after convalescent plasma transfusion, despite unidentical blood group.","PeriodicalId":76963,"journal":{"name":"AACN clinical issues in critical care nursing","volume":"71 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2022-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":"{\"title\":\"The success of non-ABO-identical convalescent plasma transfusion in coronavirus disease 2019 (COVID-19) related acute respiratory distress syndrome (CARDS): a case-report\",\"authors\":\"R. Bhurayanontachai, Pisud Siripaitoon, Narongdet Kositpantawong, S. Chusri\",\"doi\":\"10.54205/ccc.v30.254752\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Coronavirus disease 2019 (COVID-19) is pandemic with substantial fatality without specific treatment. Convalescent plasma is used to treat infectious diseases including severe acute respiratory syndrome coronavirus 1 and Middle East respiratory syndrome coronavirus infection, because of the effect of direct neutralizing and suppression of viremia, and immunomodulation effect. Although several anti-cytokine agents were suggested to improve outcomes of the patient, the unavailability of drugs will be a major problem for accessing. We reported the experience of convalescent plasma transfusion for COVID-19 related acute respiratory distress syndrome (CARDS), who refractory to standard treatment and clinically improvement after convalescent plasma transfusion, despite unidentical blood group.\",\"PeriodicalId\":76963,\"journal\":{\"name\":\"AACN clinical issues in critical care nursing\",\"volume\":\"71 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2022-03-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"1\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"AACN clinical issues in critical care nursing\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.54205/ccc.v30.254752\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"AACN clinical issues in critical care nursing","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.54205/ccc.v30.254752","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
The success of non-ABO-identical convalescent plasma transfusion in coronavirus disease 2019 (COVID-19) related acute respiratory distress syndrome (CARDS): a case-report
Coronavirus disease 2019 (COVID-19) is pandemic with substantial fatality without specific treatment. Convalescent plasma is used to treat infectious diseases including severe acute respiratory syndrome coronavirus 1 and Middle East respiratory syndrome coronavirus infection, because of the effect of direct neutralizing and suppression of viremia, and immunomodulation effect. Although several anti-cytokine agents were suggested to improve outcomes of the patient, the unavailability of drugs will be a major problem for accessing. We reported the experience of convalescent plasma transfusion for COVID-19 related acute respiratory distress syndrome (CARDS), who refractory to standard treatment and clinically improvement after convalescent plasma transfusion, despite unidentical blood group.